Drug major Dr Reddy’s Laboratories today announced that it has launched Pamorelin LA in India on December 3 under an exclusive marketing and sales agreement with Switzerland-based Debiopharm Group, a global biopharmaceutical group with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics.
Pamorelin LA is used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Pamorelin LA will be imported in bulk from Debio Recherche Pharmaceutique (Debio RP). It will be made available primarily to urologists and oncologists across India, according to a company release.